TrialArthritis research & therapy2025

The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.

Eugen Feist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.